Navigation Links
Sinovac Reports Unaudited Third Quarter 2013 Financial Results
Date:11/12/2013

fluenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 SINOVAC BIOTECH LTD.Incorporated in Antigua and  BarbudaConsolidated Balance Sheets(Unaudited)(Expressed in U.S. Dollars)30-Sep-1331-Dec-12ASSETSCurrent assets  Cash and cash equivalents

$

89,026,229

$

91,240,956  Accounts receivable – net 38,598,69123,440,135  Inventories 15,939,47210,529,476  Prepaid e
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2. Sinovac Reports Unaudited First Quarter 2012 Financial Results
3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
4. Sinovac Schedules 2012 Annual Meeting of Shareholders
5. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac Holds 2012 Annual General Meeting of Shareholders
8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
10. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
11. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 According to a ... Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, ... - Forecast to 2020", published by MarketsandMarkets, the European Injectable ... 2020 from $114.7 Billion in 2015, growing at a CAGR ... 230 market data T ables ...
(Date:7/27/2015)... and WESTLAKE VILLAGE, Calif. , July ... ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) ... has granted early termination of the waiting period under ... with respect to Allergan,s pending acquisition of KYTHERA.  ... On July 6, 2015, each of Allergan and KYTHERA ...
(Date:7/27/2015)... , July 27, 2015  SeraCare Life ... diagnostics manufacturers, announced at the 2015 AACC Annual ... partnership agreement with ViveBio, LLC, a biotechnology company ... upon ViveST™ technology.  Products enabled with ViveST™ allow ... shelf stable format.  Under the terms of the ...
Breaking Medicine Technology:European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 2SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 3
... Clinic has,clarified the methods of diagnosis and optimal ... of the brain and spinal cord that,often leads ... vasculitis,(PCNSV) can best be identified through a combination ... arteries), brain,biopsy and other laboratory studies., This ...
... at the World Muscle Society International Congress, ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company focused ... drugs targeting,post-transcriptional control mechanisms, today announced additional ... PTC124 in patients with Duchenne muscular,dystrophy (DMD) ...
Cached Medicine Technology:Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord 2Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's disease more than having ... attack, and stroke are treatable, but there is little an individual can do to ... part in a clinical trial, reports the July 2015 Harvard Women's Health Watch ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published ... Fibromyalgia, Study Says " sheds light on a possible new treatment option for people ... months of regular HBOT sessions, at least five per week, patients experienced a significant ...
(Date:7/28/2015)... ... ... Most employers have been using multi-tier prescription drug plans for many years, ... increase in the use of 4-tier plans, which typically cover the highest cost drugs, ... expected to continue, according to UBA. , UBA’s survey finds that, since 2009, the ...
(Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys today announced that their ... the EY Entrepreneur of the Year award. The award recognizes the important strides ... the innovative work they have done in incorporating new technology, processes, and procedures ...
(Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine has adopted a new ... more service offerings, updated treatment techniques, and additional state-of-the art online resources for patients. ... invasive surgical treatment of brain and spine conditions. , “Adding the word ‘pain’ ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4
... of anabolic steroids, more specifically anabolic androgen steroid (AAS) ... sebaceous glands. Sebaceous glands present in the skin // ... of the body surface. ,Anabolic steroids are ... to treat unwanted weight loss in patients with HIV. ...
... Teleradiology can soon offer a solution to the silent ... more than a good night’s sleep. // It ... subjected to middle of the night CT scans or ... emergency department. Such examinations have no doubt yielded the ...
... been raised against the use of Teflon. The Environmental Protection ... to make the substance nonsticky is a possible source of ... cookware was heated to more than 600 degrees Fahrenheit then ... ,Teflon was accidentally discovered in 1938. The Frenchman was ...
... A new law has come into existence to protect the ... McManis, J.D., IP and technology law expert, Thomas and Karole ... has come with various ideas. // This is mainly done ... promote the interest of the local communities. ...
... Sussman, Ph.D., professor anthropology in Arts & Sciences at Washington ... conditions, humans were actually peace loving race in earlier times. ... "Early Humans on the Menu," during the American Association for ... on February 18. ,In his new ...
... children that are raised in Foster homes better off ... children from the orphanages don’t grow to their full ... not irreversible - when the same children were put ... areas. ,Romania’s experiment of Foster homes, that included ...
Cached Medicine News:Health News:International Teleradiology: The Future Of Radiologic Diagnosis 2Health News:Early Man Was A Prey Rather Than A Predator 2
... These precision 4mL PYREX volumetric ... "To Contain" (TC - bottom ... - top line) to specifications ... Pipets are color-coded with colored ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Inquire...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
Medicine Products: